Fused Pyrazole Derivatives And Methods Of Treatment Of Metabolic-related Disorders Thereof

  • Published: Oct 15, 2009
  • Earliest Priority: Dec 23 2004
  • Family: 32
  • Cited Works: 0
  • Cited by: 2
  • Cites: 6
  • Additional Info: Full text
Abstract

The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of alpha-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.


Claims
Download PDF
Document Preview
Document History
  • Publication: Oct 15, 2009
  • Application: Apr 30, 2009
    US US 43370409 A
  • Priority: Apr 30, 2009
    US US 43370409 A
  • Priority: Nov 17, 2006
    US US 60118406 A
  • Priority: Dec 22, 2005
    US US 31575305 A
  • Priority: Apr 29, 2005
    US US 67652105 P
  • Priority: Dec 23, 2004
    US US 63866804 P

Download Citation


Sign in to the Lens

Feedback